ABVC BioPharma Expands Silicon Valley Operations with Multi-Product Capabilities and Job Growth Projection

ABVC BioPharma has announced that its wholly owned subsidiary BioKey has strengthened operational capabilities at its 28,176-square-foot pharmaceutical development and manufacturing facility in Silicon Valley. The Fremont, California location serves as a central component of ABVC's global chemistry, manufacturing, and controls strategy and U.S.-Asia development approach. The facility currently incorporates formulation development laboratories, analytical laboratories, quality-aligned production areas, and warehousing, with capacity for expansion to support multiple development programs executed in parallel within a single integrated U.S.-based location.

BioKey's facility operates as a single-location, multi-product development center supporting pharmaceutical formulations, botanical and plant-based products, controlled-release and specialized solid-oral dosage forms, and functional food and nutraceutical products. All activities from formulation through pilot-scale preparation are performed entirely within the United States, providing a fully domestic development pathway that aims to reduce cross-border complexities and enhance supply-chain resilience. This integrated approach is designed to be attractive to potential partners seeking U.S.-based manufacturing capabilities.

The operational capabilities include formulation development for pharmaceuticals and functional food products, process development and pilot-scale preparation, analytical testing, stability studies, quality documentation, and technical and regulatory support for U.S. and international submissions. The facility also provides cross-functional support for technology-transfer and long-term development programs. This comprehensive structure enables simultaneous support of multiple therapeutic and nutraceutical projects under coordinated oversight, creating an efficient development ecosystem.

ABVC and BioKey have outlined a medium-term development plan targeting expanded U.S.-Asia chemistry, manufacturing, and controls execution and increased participation in global pharmaceutical and functional food innovation. By 2030, the companies anticipate that BioKey's expanded activities, operational growth, and partner-supported programs will enable and support up to 1,000 jobs across formulation, analytical development, quality operations, regulatory support, documentation, data management, and supply-chain coordination. This represents significant potential job creation in the Silicon Valley biopharmaceutical sector.

The Fremont facility features over 12,054 square feet of expansion-ready space that can accommodate additional analytical capacity, expanded development and production workflows, technology-transfer and documentation centers, and functional food and clinical material preparation zones. Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that BioKey serves as an essential pillar of ABVC's global development strategy, providing a fully U.S.-based platform capable of supporting multiple pharmaceutical, botanical, and functional food programs from early formulation through pilot preparation. Investors can find more detailed information about the Company and risk factors in the Company's filings with the Securities and Exchange Commission available at https://www.sec.gov.